pralidoxime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2231 | 51-15-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| Vd (Volume of distribution) | 0.80 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 9 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.40 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 655 mg/mL | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 11, 1964 | FDA | BAXTER HLTHCARE CORP |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V03AB04 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes |
| FDA MoA | N0000000080 | Cholinesterase Reactivators |
| MeSH PA | D000931 | Antidotes |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D002801 | Cholinesterase Reactivators |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D020011 | Protective Agents |
| CHEBI has role | CHEBI:38323 | cholinergic drugs |
| CHEBI has role | CHEBI:50241 | cholinesterase reactivators |
| CHEBI has role | CHEBI:90753 | antidote to acetylcholinesterase inhibitor poisoning |
| FDA EPC | N0000175742 | Cholinesterase Reactivator |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Organophosphate poisoning | indication | 8260003 | |
| Poisoning due to Nerve Agent | indication | ||
| Cholinesterase Inhibitors Toxicity | indication | ||
| Organophosphorous Overdose | indication | ||
| Atrial flutter | contraindication | 5370000 | |
| Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Acute nephropathy | contraindication | 58574008 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Pyloric obstruction | contraindication | 244815007 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Myocardial infarction in recovery phase | contraindication | 418044006 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Poisoning caused by pesticides and chemicals of the organophosphate class which have anticholinesterase activity | Indication |
| Dogs | Poisoning caused by pesticides and chemicals of the organophosphate class which have anticholinesterase activity | Indication |
| Horses | Poisoning caused by pesticides and chemicals of the organophosphate class which have anticholinesterase activity | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Protopam | Zoetis Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.87 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Acetylcholinesterase | Enzyme | ACTIVATOR | Kd | 4.59 | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D00469 | KEGG_DRUG |
| 94-63-3 | SECONDARY_CAS_RN |
| 14018-50-9 | SECONDARY_CAS_RN |
| 4018484 | VANDF |
| 4019900 | VANDF |
| C0071808 | UMLSCUI |
| CHEBI:8354 | CHEBI |
| CHEMBL1420 | ChEMBL_ID |
| DB00733 | DRUGBANK_ID |
| CHEMBL14577 | ChEMBL_ID |
| 135398747 | PUBCHEM_CID |
| C028797 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7597 | IUPHAR_LIGAND_ID |
| P7MU9UTP52 | UNII |
| 34345 | RXNORM |
| 5339 | MMSL |
| d01409 | MMSL |
| 001095 | NDDF |
| 004542 | NDDF |
| 007941 | NDDF |
| 1186942004 | SNOMEDCT_US |
| 17356001 | SNOMEDCT_US |
| 387527005 | SNOMEDCT_US |
| 922004 | SNOMEDCT_US |
| CHEMBL748 | ChEMBL_ID |
| 851 | INN_ID |
| 25615-00-3 | SECONDARY_CAS_RN |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Protopam Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60977-141 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | NDA | 26 sections |
| Protopam Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60977-141 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | NDA | 26 sections |